This analysis examines the historical and forecast performance for UCB in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark UCB's performance against key rivals in the ethical pharmaceutical sector Assess UCB's M&A-driven diversification into the biopharmaceuticals sector, under-scored by the impending launch of Cimzia Analyze UCB's impressive forecast sales growth performance over 2006-12, with revenues expected to grow at a CAGR of 11.4%